Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tae Hatsuyama"'
Autor:
Kengo Umehara, Kaori Yama, Keisuke Goto, Azusa Wakamoto, Tae Hatsuyama, Osamu Honjo, Toyohiro Saikai, Akihisa Fujita, Hideki Sato
Publikováno v:
Cancer Control, Vol 28 (2021)
Introduction: Corticosteroids are used to treat immune-related adverse events (irAEs) associated with nivolumab. However, patients with non-small-cell lung cancer who are administered corticosteroids before the initiation of nivolumab treatment are c
Externí odkaz:
https://doaj.org/article/ecec087538944c1ea8719ec7d92f55e7
Autor:
YASUHISA HASHINO, TAKUMU MATUSHITA, TAE HATSUYAMA, AZUSA WAKAMOTO, KEISUKE GOTO, TAKANOBU HOSHI, KUNINORI IWAYAMA, KOICHI OHTAKI, TAKAKI TODA, HIDEKI SATO
Publikováno v:
In Vivo; Mar/Apr2024, Vol. 38 Issue 2, p864-872, 9p
Autor:
ATSUYA SHIMIZU, MIYU FUKASAWA, KOHARU MITANI, KEISUKE GOTO, AZUSA WAKAMOTO, TAE HATSUYAMA, TAKANOBU HOSHI, ISAO HASEGAWA, HIDEKI SATO
Publikováno v:
In Vivo; Jan/Feb2024, Vol. 38 Issue 1, p418-424, 7p
Autor:
YASUHISA HASHINO, TAE HATSUYAMA, KUNINORI IWAYAMA, TAKANOBU HOSHI, AZUSA WAKAMOTO, KOICHI OHTAKI, TAKAKI TODA, HIDEKI SATO
Publikováno v:
In Vivo; Nov/Dec2023, Vol. 37 Issue 6, p2669-2677, 8p
Autor:
Tae Hatsuyama, Takaki Toda, Azusa Wakamoto, Yuji Mukai, Hideki Sato, Tatsunari Yoshida, Akihisa Fujita, Nobuo Inotsume
Publikováno v:
Therapeutic Drug Monitoring. 43:772-779
Background Routine therapeutic drug monitoring is a promising approach for the rational use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase (ALK) inhibitors. The purpose of this study was to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d88c635eb5c82dc8d0b7387b1f0125a
https://doi.org/10.1097/ftd.0000000000000895
https://doi.org/10.1097/ftd.0000000000000895
Autor:
Tae Hatsuyama, Azusa Wakamoto, Keisuke Goto, Toyohiro Saikai, Kaori Yama, Kengo Umehara, Hideki Sato, Osamu Honjo, Akihisa Fujita
Publikováno v:
Cancer Control, Vol 28 (2021)
Cancer Control : Journal of the Moffitt Cancer Center
Cancer Control : Journal of the Moffitt Cancer Center
Introduction: Corticosteroids are used to treat immune-related adverse events (irAEs) associated with nivolumab. However, patients with non-small-cell lung cancer who are administered corticosteroids before the initiation of nivolumab treatment are c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c62470cb18a06c857b2c73baac7eef6
https://doi.org/10.1177/1073274820985790
https://doi.org/10.1177/1073274820985790
Autor:
Tae Hatsuyama, Osamu Honjo, Takayuki Toda, Shiori Noomote, Keisuke Gto, Hideki Sato, Kengo Umehara, Yasuka Okazaki, Azusa Wakamoto, Yuki Okayama
Publikováno v:
Annals of Oncology. 30:vi140-vi141
Background Since osimertinib significantly prolonged progression free survival compared with conventional EGFR-TKI and was well-tolerated, it was approved in August 2018 as the primary treatment in EGFR mutation positive non-small cell lung cancer. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25d3e15f4d04ce8fb9b85b18c3173b54
https://doi.org/10.1093/annonc/mdz343.107
https://doi.org/10.1093/annonc/mdz343.107
Autor:
Kengo, Umehara, Azusa, Wakamoto, Tae, Hatsuyama, Hideki, Sato, Michiya, Kobayashi, Akihisa, Fujita, Kyuichiro, Sekine
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 43(8)
Palonosetron(Palo)is a second-generation 5-hydroxytryptamine 3 receptor antagonist(5-HT3RA)effective in suppressing chemotherapy-induced nausea and vomiting in both acute and delayed phases.Most studies have reported Palo as an effective antiemetic f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2c5c8b8836ce77d84f97fa6c4c638b6a
https://pubmed.ncbi.nlm.nih.gov/27539038
https://pubmed.ncbi.nlm.nih.gov/27539038
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 42(6)
Guidelines for antiemetic therapy, such as the American Society of Clinical Oncology (ASCO) guidelines, recommend that aprepitant, an NK1 receptor antagonist, should be used in addition to conventional antiemetic therapy for acute and delayed nausea/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ca25cf913208fa366a757ac8cc1f809d
https://pubmed.ncbi.nlm.nih.gov/26199245
https://pubmed.ncbi.nlm.nih.gov/26199245
Autor:
Hideki, Sato, Keiko, Wada, Kengo, Umehara, Keisuke, Otsu, Azusa, Wakamoto, Tae, Hatsuyama, Akihisa, Fujita, Kyuichiro, Sekine
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 40(6)
Aprepitant is a NK1 receptor-antagonist with a novel mechanism of action for chemotherapy-induced nausea and vomiting (CINV), and is recommended as a prophylactic by many international and domestic guidelines. However, domestic clinical trials of apr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5998044d090a9a284e1030cf4833105e
https://pubmed.ncbi.nlm.nih.gov/23863648
https://pubmed.ncbi.nlm.nih.gov/23863648